SPMS took part in the InterActive Workshop of the European initiative Gravitate-Health, held in Rome in June 2025, bringing together more than 50 European partners. This meeting focused on analysing the project’s progress, aligning the functionalities of the digital solution Gravitate Lens (G-lens®), and defining strategies to ensure its sustainability after the project’s conclusion.
As part of SPMS’s commitment to digital health innovation, the G-lens® solution was integrated into the SNS24 app, providing electronic product information (ePI) about medicines according to the established standard. This initiative aims to facilitate citizens’ access to reliable and regulated information, promoting the usability and accessibility of patient leaflets, with a direct impact on public health and disease management.
Over two days of collaborative work, the consortium explored the most recent developments of the G-lens® functionality – a solution aimed at adapting the information presented in the electronic package leaflet (ePI) of medicines to the individual characteristics of each citizen.
One of the main highlights was the discussion of sustainability models for ensuring sustainability beyond the project’s end. The assets, technical resources, and knowledge generated throughout the Gravitate-Health European action were identified with the aim of ensuring continuity and future adoption. The debate also covered approaches to stakeholder engagement, interoperability strategies, and the role of structured information in the adaptation of package leaflets.
SPMS’s presence at this event reinforces the national commitment to digital transformation in healthcare and to the development of citizen-centred solutions.
Disclaimer:
The Gravitate-Health project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 945334. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Datapharm Limited. The total budget is 19.4 M € for a project duration of 60 months. Views and opinions expressed do not necessarily reflect those of the IMI nor of the European Union, EFPIA, or Datapharm Limited. Neither the European Union nor the granting authority can be held responsible for them.
